REYATAZ

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, France, Hong Kong, Ireland, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States, South Africa

Active ingredients

The drug REYATAZ contains one active pharmaceutical ingredient (API):

1 Atazanavir
UNII 4MT4VIE29P - ATAZANAVIR SULFATE

Atazanavir is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag-Pol proteins in HIV-1 infected cells, thus preventing formation of mature virions and infection of other cells.

Read about Atazanavir

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
REYATAZ Hard capsules European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J05AE08 Atazanavir J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 10321F, 10349Q
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 505107902111212, 505107903116315
Country: CA Health Products and Food Branch Identifier(s): 02248610, 02248611, 02294176
Country: EE Ravimiamet Identifier(s): 1208168, 1208179, 1208180, 1208191, 1368086, 1402489, 1722495, 1722507
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 03267004, 03267006, 03267008
Country: FR Base de données publique des médicaments Identifier(s): 66745660, 68301348, 69443966
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 136417, 73374, 73377
Country: HK Department of Health Drug Office Identifier(s): 52846, 56784
Country: JP 医薬品医療機器総合機構 Identifier(s): 6250023M1026, 6250023M2022
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1030704, 1030705, 1030706, 1030707, 1030708, 1030709, 1032112, 1032113, 1056564, 1080849, 1080850
Country: NL Z-Index G-Standaard, PRK Identifier(s): 74330, 74349, 86479
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 11007, 11008, 13160
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100125810, 100125827, 100125833, 100193409, 100398726
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W65567001, W65567002, W65568001, W65568002, W65569001, W65569002, W65569003
Country: SG Health Sciences Authority Identifier(s): 12520P, 12521P, 13560P
Country: US FDA, National Drug Code Identifier(s): 0003-3622, 0003-3624, 0003-3631, 0003-3638, 67296-1236
Country: ZA Health Products Regulatory Authority Identifier(s): A39/20.2.8/0088, A39/20.2.8/0089

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.